After cardiac stents, 14 more medical devices may see price
After cardiac stents, around 14 more medical devices that are rampantly sold at inflated rates in hospitals, could see a price regulation in the coming months. The list includes orthopedic implants, intraocular lenses and artificial heart valves to consumables such as syringes, needles and catheters.

The National Pharmaceutical Pricing Authority (NPPA) has begun scrutiny of such devices, even asking makers to log in every detail about their manufacture and cost.

In terms of steep retail markups, orthopedic implants probably come closest to cardiac stents. A selected imported hip and knee implants easily see profit margins in the range of 500-1,000%, industry insiders said. Indian implants too are sold at margins of 200-500%, though surgeons often prefer imported types. The cost of intraocular lenses also varies widely depending on the hospital and the operating surgeon.
Dr. p●●●●j k●●●r and 3 others like this
Dr. S●●●n k●●●r J●a
Dr. S●●●n k●●●r J●a Paediatrics
Price control of treatment is demand of time for developing country like us.
Feb 20, 2017Like
Dr. bl p●●●●d
Dr. bl p●●●●d General Surgery
But where is the control, where is the punishment for violates,
Feb 20, 2017Like